WASHINGTON (AP) - The Food and Drug Administration announced Friday it will convene a public meeting in October to review the risks of psychiatric and behavioral side effects with Pfizer's anti-smoking drug Chantix.
The agency says in a federal notice it will convene its panel of psychiatric drug experts to discuss the pill's risks and how to manage them.
Since 2009 Chantix has carried the government's strongest safety warning due to links to hostility, agitation, depression and suicidal thoughts. The warning was added after the FDA received dozens of reports of suicide and suicidal behavior among patients taking Chantix.
At that time the FDA also required Pfizer to conduct additional studies.
A spokeswoman for Pfizer said Friday that the company recently submitted new data to the FDA designed to show the drug's safety.
To comment, the following rules must be followed:
Comments may be monitored for inappropriate content, but the station is under no legal obligation to do so.
If you believe a comment violates the above rules, please use the Flagging Tool to alert a Moderator.
Flagging does not guarantee removal.
Multiple violations may result in account suspension.
Decisions to suspend or unsuspend accounts are made by Station Moderators.
Questions may be sent to email@example.com.
Please provide detailed information.
All comments must adhere to the WSAW.com discussion rules.